View
232
Download
0
Category
Preview:
Citation preview
7/31/2019 A 110525 Meden Ttotg
1/150
gdFourth edition
TreaTmenT of Tuberculosis
7/31/2019 A 110525 Meden Ttotg
2/150
7/31/2019 A 110525 Meden Ttotg
3/150
Tratmt o tbrco
GuidelinesForth to
7/31/2019 A 110525 Meden Ttotg
4/150
WHO Library Cataloguing-in-Publication Data:
reatment o tuberculosis: guidelines 4th ed.
WHO/HM/B/2009.420
1.Antitubercular agents administration and dosage. 2.uberculosis,
Pulmonary drug therapy. 3.National health programs. 4.Patient compliance.
5.Guidelines. I.World Health Organization. Stop B Dept.
ISBN 978 92 4 154783 3 (NLM classication: WF 360)
World Health Organization 2010
All rights reserved. Publications o the World Health Organization can be obtained rom WHO Press,
World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 4857; e-mail:
bookorders@who.int). Requests or permission to reproduce or translate WHO publications whether
or sale or or noncommercial distribution should be addressed to WHO Press, at the above address
(ax: +41 22 791 4806; e-mail: permissions@who.int).
Te designations employed and the presentation o the material in this publication do not imply the
expression o any opinion whatsoever on the part o the World Health Organization concerning thelegal status o any country, territory, city or area or o its authorities, or concerning the delimitation o
its rontiers or boundaries. Dotted lines on maps represent approximate border lines or which there may
not yet be ull agreement.
Te mention o specic companies or o certain manuacturers products does not imply that they are
endorsed or recommended by the World Health Organization in preerence to others o a similar nature
that are not mentioned. Errors and omissions excepted, the names o proprietary products are distin-
guished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to veriy the inormation
contained in this publication. However, the published material is being distributed without warranty o
any kind, either expressed or implied. Te responsibility or the interpretation and use o the materiallies with the reader. In no event shall the World Health Organization be liable or damages arising rom
its use.
Designed by minimum graphics
Printed in .
7/31/2019 A 110525 Meden Ttotg
5/150
iii
: :
Cott
Abbrvato v
Ackowgmt v
Forwor x
Eective s 1
1. Itcti 15
1.1 Chaptr objctv 15
1.2 Prpo o th g 15
1.3 Targt ac 15
1.4 scop 15
1.5 Why a w to? 15
1.6 Mthooogy 18
1.7 itratoa staar or Tbrco Car 21
1.8 expry at 21
2. Cse efitis 23
2.1 Chaptr objctv 23
2.2 Prpo o fg a TB ca 23
2.3 Ca fto 23
2.4 Aatomca t o TB a 24
2.5 Bactroogca rt 25
2.6 Htory o prvo tratmt: patt rgtrato grop 262.7 HiV tat 28
3. St tetet egies 29
3.1 Chaptr objctv 29
3.2 Am o tratmt 29
3.3 eta at-TB rg 29
3.4 staar rgm or f patt grop 31
3.5 nw patt 323.6 Prvoy trat patt a mtrg rtac 36
3.7 staar rgm or prvoy trat patt 38
3.8 Ovra corato ctg a cotry taar rgm 42
7/31/2019 A 110525 Meden Ttotg
6/150
iv
TrEaTmEnT o TubErCuloSIS: GuIdElInES
4. mitig ig tetet 53
4.1 Chaptr objctv 53
4.2 Motorg th patt 53
4.3 Ag tratmt rpo w a prvoy trat pmoary
TB patt, a actg o th rt 53
4.4 extrapmoary TB 57
4.5 Rcorg taarz tratmt otcom 57
4.6 Cohort aay o tratmt otcom 57
4.7 Maagmt o tratmt trrpto 59
4.8 Prvto o avr ct o rg 59
4.9 Motorg a rcorg avr ct 604.10 symptom-ba approach to maagg -ct o at-TB rg 60
5. C-geet HIV ctive Tb isese 65
5.1 Chaptr objctv 65
5.2 HiV ttg a cog or allpatt kow or pct to hav TB 65
5.3 HiV prvto TB patt 67
5.4 TB tratmt pop vg wth HiV 67
5.5 Co-trmoxazo prvtv thrapy 695.6 Atrtrovra thrapy 69
5.7 drg cptbty ttg 71
5.8 Patt motorg rg TB tratmt 71
5.9 Corato wh TB ago pop vg wth HiV who ar
aray rcvg atrtrovra thrapy 72
5.10 HiV-rat prvto, tratmt, car a pport 72
6. Spevisi ptiet sppt 75
6.1 Chaptr objctv 75
6.2 Ro o th patt, TB programm ta , th commty a othr provr 75
6.3 sprv tratmt 77
6.4 ug a patt-ctr approach to car a tratmt vry 78
6.5 Prvto o tratmt trrpto 80
7. Tetet g-esistt tecsis 83
7.1 Chaptr objctv 83
7.2 Gr lght Commtt itatv 83
7.3 Grop o rg to trat MdR-TB 84
7.4 Gra prcp gg a MdR-TB tratmt rgm 86
7/31/2019 A 110525 Meden Ttotg
7/150
v
7.5 Programmatc tratg or tratmt o MdR-TB 86
7.6 scto o th cotry taar MdR-TB tratmt rgm 89
7.7 scto o vaz MdR-TB rgm 89
7.8 Motorg th MdR-TB patt 91
7.9 drato o tratmt or MdR-TB 91
7.10 Tratg TB wth rtac pattr othr tha MdR 92
7.11 Rcorg a rportg rg-rtat TB ca, vaato o otcom 92
8. Tetet etp Tb Tb i speci sittis 95
8.1 Chaptr objctv 95
8.2 Tratmt o xtrapmoary TB 95
8.3 importat rg tracto 96
8.4 Tratmt rgm pca tato 97
aees 101
1. eta frt- attbrco rg 103
2. smmary o vc a corato ryg th rcommato 115
3. TB tratmt otcom 131
4. impmtato a vaato o th orth to 1335. sggto or tr rarch 141
6. Mmbr o th G Grop 145
ConTEnTS
7/31/2019 A 110525 Meden Ttotg
8/150
vii
AFB acid-ast bacilli
AIDS acquired immunodeciency syndrome
AR antiretroviral therapy
DO directly observed treatment
DOS the internationally agreed strategy or B control
DRS drug resistance surveillance
DS drug susceptibility testing
E ethambutol
EPB extrapulmonary tuberculosis
EQA external quality assurance
FDC xed-dose combination
GLC Green Light Committee
H isoniazid
HIV human immunodeciency virus
ISC International Standards or uberculosis Care
MDR multidrug resistance
MDR-B multidrug-resistant tuberculosis
NNRI non-nucleoside reverse transcriptase inhibitor
NRI nucleoside reverse transcriptase inhibitor
NP national tuberculosis control programmePB pulmonary tuberculosis
R riampicin
S streptomycin
B tuberculosis
B/HIV HIV-related B
XDR-B extensively drug-resistant tuberculosis
Z pyrazinamide
: :
Abbrvato
7/31/2019 A 110525 Meden Ttotg
9/150
viii
Te Stop B Department o the World Health Organization grateully acknowledges
the members o the Guidelines Group (listed in Annex 6), including Jeremiah Muh-
wa Chakaya, the Chairperson.
Richard Menzies (McGill University, Montreal, Canada), Karen Steingart and Phil-
lip Hopewell (University o Caliornia, San Francisco, USA) and Andrew Nunn and
Patrick Phillips (British Medical Research Council) led the teams that compiled, syn-thesized and evaluated the evidence underlying each recommendation.
Suzanne Hill and Holger Schnemann acilitated the meeting o the Guidelines
Group.
Useul eedback was obtained rom the External Review Group (also listed in An-
nex 6).
Additional eedback and support were provided by the Guidelines Review Commit-
tee (Chair, Suzanne Hill; Secretariat, Faith McLellan).
Publication o the guidelines was supported in part by a nancial contribution rom
the Global Fund to Fight AIDS, uberculosis and Malaria.
Te document was prepared by Sarah Royce and Malgorzata Grzemska.
Dorris Ortega provided secretarial support.
: :
Ackowgmt
7/31/2019 A 110525 Meden Ttotg
10/150
i
: :
Forwor
Te World Health Organizations Stop B Department has prepared this ourth
edition oreatment o tuberculosis: guidelines, adhering ully to the new WHO proc-
ess or evidence-based guidelines. Several important recommendations are being
promoted in this new edition.
First, the recommendation to discontinue the regimen based on just 2 months o
riampicin (2HRZE/6HE) and change to the regimen based on a ull 6 months oriampicin (2HRZE/4HR) will reduce the number o relapses and ailures. Tis will
alleviate patient suering resulting rom a second episode o tuberculosis (B) and
conserve patient and programme resources.
Second, this ourth edition conrms prior WHO recommendations or drug suscep-
tibility testing (DS) at the start o therapy or all previously treated patients. Finding
and treating multidrug-resistant B (MDR-B) in previously treated patients will
help to improve the very poor outcomes in these patients. New recommendations
or the prompt detection and appropriate treatment o (MDR-B) cases will also
improve access to lie-saving care. Te retreatment regimen with rst-line drugs
(ormerly called Category 2 regimen) is ineective in MDR-B; it is thereore criti-
cal to detect MDR-B promptly so that an eective regimen can be started.
Tird, detecting MDR-B will require expansion o DS capacity within the context
o country-specic, comprehensive plans or laboratory strengthening. Tis ourth
edition provides guidance or treatment approaches in the light o advances in lab-
oratory technology and the countrys progress in building laboratory capacity. In
countries that use the new rapid molecular-based tests, DS results or riampicin/
isoniazid will be available within 12 days and can be used in deciding which regimenshould be started or the individual patient. Rapid tests eliminate the need to treat in
the dark during the long wait or results o DS by other methods (weeks or liquid
media methods or months or solid media methods).
Because o the delays in obtaining results, this new edition recommends that coun-
tries using conventional DS methods should start treatment with an empirical regi-
men. I there is a high likelihood o MDR-B, empirical treatment with an MDR
regimen is recommended until DS results are available. Drug resistance surveil-
lance (DRS) data or surveys will be required to identiy subgroups o B patientswith the highest prevalence o MDR-B, such as those whose prior treatment has
ailed. Implementation o these recommendations will require every country to in-
clude an MDR-B regimen in its standards or treatment in collaboration with the
Green Light Committee Initiative.
7/31/2019 A 110525 Meden Ttotg
11/150
TrEaTmEnT o TubErCuloSIS: GuIdElInES
Fourth, diagnosing MDR-B cases among previously treated patients and providing
eective treatment will greatly help in halting the spreado MDR-B. Tis edition
also addresses the prevention oacquiredMDR-B, especially among new B patients
who already have isoniazid-resistant Mycobacterium tuberculosis when they starttreatment. Te meta-analyses that orm the evidence base or this revision revealed
that new patients with isoniazid-resistant B have a greatly increased risk o acquiring
additional drug resistance. o prevent amplication o existing drug resistance, this
edition includes the option o adding ethambutol to the continuation phase o treat-
ment or new patients in populations with high prevalence o isoniazid resistance.
In addition, the daily dosing recommended or the intensive phase may also help in
reducing acquired drug resistance, especially in patients with pretreatment isoniazid
resistance.
Finally, this edition strongly rearms prior recommendations or supervised treat-
ment, as well as the use o xed-dose combinations o anti-B drugs and patient kits
as urther measures or preventing the acquisition o drug resistance.
Use o the new WHO process or evidence-based guidelines revealed many key un-
answered questions. What is the best way to treat isoniazid-resistant B and pre-
vent MDR? What is the optimal duration o B treatment in HIV-positive patients?
Which patients are most likely to relapse and how can they be detected and treated?
Identication o such crucial questions or the uture research agenda is an important
outcome o this revision and will require careul ollow-up to ensure that answerswill be provided to urther strengthen B care practices.
As new studies help to ll these gaps in knowledge, new laboratory technology is
introduced, and new drugs are discovered, these guidelines will be updated and
revised. In the meantime, WHO pledges its ull support to helping countries to im-
plement and evaluate this ourth edition oreatment o tuberculosis: guidelines and
to use the lessons learnt to improve access to high-quality, lie-saving B care.
Dr Mario Raviglione
DirectorStop B Department
7/31/2019 A 110525 Meden Ttotg
12/150
1
Major progress in global tuberculosis (B) control ollowed the widespread imple-
mentation o the DOS strategy. Te Stop B Strategy, launched in 2006, builds upon
and enhances the achievements o DOS. New objectives include universal access to
patient-centred treatment and protection o populations rom B/HIV and multi-
drug-resistant B (MDR-B). Te Stop B Strategy and the Global Plan to imple-
ment the new strategy make it necessary to revise the third edition oreatment o
tuberculosis: guidelines or national programmes, published in 2003.
Creation o the ourth edition ollows new WHO procedures or guidelines develop-
ment. With input rom a group o external experts the Guidelines Group WHO
identied seven key questions, and systematic reviews were conducted or each ques-
tion. Te Guidelines Group based its recommendations on the quality o the evidence
(assessed according to the GRADE methodology), patient values, and costs, as well
judgements about trade-os between benets and harms. Recommendations were
rated as strong or conditional.
Te evidence and considerations underlying each recommendation are summarized
in Annex 2.
A strong recommendation is one or which desirable eects o adherence to the rec-
ommendation clearly outweigh the undesirable eects. Te strong recommendations
in this edition use the words should or should not. No alternatives are listed.
A conditional recommendation is one or which the desirable eects o adherence to
the recommendation probably outweigh the undesirable eects but the trade-os are
uncertain.
Reasons or uncertainty can include:
lack o high-quality evidence to support the recommendation;
limited benets o implementing the recommendation;
costs not justied by the benets;
imprecise estimates o benet.
A weak recommendation is one or which there is insucient evidence and it is based
on eld application and expert opinion. Recommendations or which the quality o
evidence was not assessed in line with the GRADE methodology are not rated.
Conditional and weak recommendations use the words may. For several o the con-
ditional recommendations, alternatives are listed.
: :
exctv mmary
7/31/2019 A 110525 Meden Ttotg
13/150
2
TrEaTmEnT o TubErCuloSIS: GuIdElInES
Te recommendations that address each o the seven questions are listed below,
and also appear in bold text in Chapter 3 (Standard treatment regimens), Chapter 4
(Monitoring during treatment) and Chapter 5 (Co-management o HIV and active
B). Areas outside the scope o the seven questions, as well as the remaining chapters,have been updated with current WHO B policies and recent reerences but were
not the subject o systematic literature reviews or o new recommendations by the
Guidelines Group.
Qesti 1. dti ipici i ew ptiets
Should new pulmonary B patients be treated with the 6-month riampicin regimen
(2HRZE/4HR) or the 2-month riampicin regimen (2HRZE/6HE)?
L
Recommendation 1.1New patients with pulmonary B should receive a regimen containing 6 months
o riampicin: 2HRZE/4HR
(Strong/High grade o evidence)
Remark a: Recommendation 1.1 also applies to extrapulmonary B, except B o
the central nervous system, bone or joint or which some expert groups suggest
longer therapy (see Chapter 8).
Remark b: WHO recommends that national B control programmes ensure that
supervision and support are provided or all B patients in order to achieve com-
pletion o the ull course o therapy.
Remark c: WHO recommends drug resistance surveys (or surveillance) or moni-
toring the impact o the treatment programme as well as or designing standard
regimens.
L Recommendation 1.2
Te 2HRZE/6HE treatment regimen should be phased out
(Strong/High grade o evidence)
Qesti 2. dsig eqec i ew ptiets
When a country selects 2HRZE/4HR, should patients be treated with a daily or three
times weekly intensive phase?
L Recommendation 2.1
Wherever easible, the optimal dosing requency or new patients with pulmo-
nary B is daily throughout the course o therapy
(Strong/High grade o evidence)
Tere are two alternatives to Recommendation 2.1:
7/31/2019 A 110525 Meden Ttotg
14/150
3
ExECuTIVE Summary
L Recommendation 2.1A
New patients with pulmonary B may receive a daily intensive phase
ollowed by a three times weekly continuation phase [2HRZE/4(HR)3], pro-
vided that each dose is directly observed(Conditional/High and moderate grade o evidence)
L Recommendation 2.1B
Tree times weekly dosing throughout therapy [2(HRZE)3/4(HR)
3] may be
used as another alternative to Recommendation 2.1, provided that every
dose is directly observed and the patient is NO living with HIV or living in
an HIV-prevalent setting
(Conditional/High and moderate grade o evidence)
Remark a: reatment regimens or B patients living with HIV or living in
HIV-prevalent settings are discussed in Recommendation 4 and Chapter 5.
Remark b: In terms o dosing requency or HIV-negative patients, the system-
atic review ound little evidence o dierences in ailure or relapse rates with
daily or three times weekly regimens (see Annex 2). However, rates o acquired
drug resistance were higher among patients receiving three times weekly dosing
throughout therapy than among patients who received daily drug administra-
tion throughout treatment. Moreover, in patients with pretreatment isoniazid
resistance, three times weekly dosing during the intensive phase was associ-
ated with signicantly higher risks o ailure and acquired drug resistance than
daily dosing during the intensive phase.
L Recommendation 2.2
New patients with B should not receive twice weekly dosing or the ull course
o treatment unless this is done in the context o ormal research
(Strong/High grade o evidence)
Remark: Te available evidence showed equivalent ecacy o daily intensive-phase dosing ollowed by two times weekly continuation phase. However, twice
weekly dosing is not recommended on operational grounds, since missing one
dose means the patient receives only hal the regimen.
Qesti 3. Iiti egie i cties with high eves isiziesistce
In countries with high levels o isoniazid resistance in new B patients, should the
continuation phase (containing isoniazid and riampicin) be changed in the stan-dard treatment o all new patients, in order to prevent the development o multidrug
resistance?1
1 Tis question applies to countries where isoniazid susceptibility testing in new patients is not done (orresults are not avai lable) beore the continuation phase begins.
7/31/2019 A 110525 Meden Ttotg
15/150
4
TrEaTmEnT o TubErCuloSIS: GuIdElInES
L Recommendation 3
In populations with known or suspected high levels o isoniazid resistance, new
B patients may receive HRE as therapy in the continuation phase as an accept-
able alternative to HR(Weak/Insucient evidence, expert opinion)
Remark a: While there is a pressing need to prevent multidrug resistance (MDR),
the most eective regimen or the treatment o isoniazid-resistant B is not known.
Tere is inadequate evidence to quantiy the ability o ethambutol to protect
riampicin in patients with pretreatment isoniazid resistance. Te evidence or
ocular toxicity rom ethambutol was not systematically reviewed or this revision,
but the risk o permanent blindness exists. Tus, urther research (see Annex 5) is
urgently needed to dene the level o isoniazid resistance that would warrant theaddition o ethambutol (or other drugs) to the continuation phase o the standard
new patient regimen in B programmes where isoniazid drug susceptibility test-
ing is not done (or results are unavailable) beore the continuation phase begins.
Remark b: Daily (rather than three times weekly) intensive-phase dosing may also
help prevent acquired drug resistance in B patients starting treatment with iso-
niazid resistance. Te systematic review (Annex 2) ound that patients with isoni-
azid resistance treated with a three times weekly intensive phase had signicantly
higher risks o ailure and acquired drug resistance than those treated with daily
dosing during the intensive phase.
Qesti 4. Tb tetet i pess ivig with HIV
Should intermittent regimens be used or persons living with HIV? What should be
the duration o B treatment in people living with HIV?
Remark: Current WHO recommendations promoting the use o antiretroviral thera-
py in B patients living with HIV should be put rapidly into practice.
L Recommendation 4.1B patients with known positive HIV status and all B patients living in HIV-
prevalent settings should receive daily B treatment at least during the inten-
sive phase
(Strong/High grade o evidence)
Remark: HIV-prevalent settings are dened as countries, subnational administra-
tive units, or selected acilities where the HIV prevalence among adult pregnant
women is 1% or among B patients is 5%.
L Recommendation 4.2
For the continuation phase, the optimal dosing requency is also daily or these
patients
(Strong/High grade o evidence)
7/31/2019 A 110525 Meden Ttotg
16/150
5
L Recommendation 4.3
I a daily continuation phase is not possible or these patients, three times
weekly dosing during the continuation phase is an acceptable alternative
(Conditional/High and moderate grade o evidence)
L Recommendation 4.4
It is recommended that B patients who are living with HIV should receive at least
the same duration o B treatment as HIV-negative B patients
(Strong/High grade o evidence)
Remark a: Some experts recommend prolonging B treatment in persons living
with HIV (see Chapter 5).
Remark b: Previously treated B patients who are living with HIV should receivethe same retreatment regimens as HIV-negative B patients.
Recommendations 14 (as they relate to new patients) are summarized in able A
below, and shown in ables 3.2 and 3.3 in Chapter 3.
Tab A STAndArd regimen And doSing requency or new TB pATienTS
Itesive phse Ctiti phse Cets
2 ths HrZea 4 ths Hr
2 ths HrZe 4 ths Hre As ts th hh vs saz ssta TB atts, a
h saz sstbt tst atts s t ( sts a
avaab) b th tat hasbs
a wHo s ss thabt th tsv has tatt
atts th -avta, sa-atv a TB taa sas h a k
t b HiV-atv.
dsig eqecCets
Itesive phse Ctiti phse
da da ota
da 3 ts k Atab atatv a TB att
v t bsv tha
3 ts k 3 ts k Atab atatv v that th
att s v t bsv thaa s noT v th HiV v a HiV-
vat stt (schat 5)
Note: da (ath tha th ts k) tsv-has s a h t vt a
ssta TB atts stat tatt th saz ssta (s A 2).
ExECuTIVE Summary
7/31/2019 A 110525 Meden Ttotg
17/150
6
TrEaTmEnT o TubErCuloSIS: GuIdElInES
Qesti 5. Spt itig ig Tb tetet se-psitivep Tb ptiets
In pulmonary B patients who are initially smear positive, how eective is moni-
toring sputum specimens or predicting relapse, ailure and pretreatment isoniazidresistance?
Figures 4.1 and 4.2 in Chapter 4 illustrate Recommendations 5.15.3.
L Recommendation 5.1
For smear-positive pulmonary B patients treated with rst-line drugs, sputum
smear microscopy may be perormed at completion o the intensive phase o
treatment
(Conditional/High and moderate grade o evidence)
Remark a: Tis recommendation applies both to new patients treated with regimens
containing 6 months o riampicin, and to patients returning aer deault or relapse
and now receiving the 8-month retreatment regimen (2HRZES/1HRZE/5HRE).
Note that the end o the intensive phase may be at 2 months or 3 months, depend-
ing on the regimen.
Remark b: Available evidence showed that smear status at the end o the intensive
phase is a poor predictor o relapse, ailure and pretreatment isoniazid resistance.
Nonetheless, WHO continues to recommend perorming smear microscopy atthis stage because a positive smear should trigger an assessment o the patient,
as well as additional sputum monitoring (see Recommendations 5.2 and 5.3).
Sputum smear conversion at the end o the intensive phase is also an indicator o
B programme perormance.
L Recommendation 5.2
In new patients, i the specimen obtained at the end o the intensive phase
(month 2) is smear-positive, sputum smear microscopy should be obtained at
the end o the third month
(Strong/High grade o evidence)
L Recommendation 5.3
In new patients, i the specimen obtained at the end o month 3 is smear-positive,
sputum culture and drug susceptibility testing (DS) should be perormed
(Strong/High grade o evidence)
Remark: National B control programmes (NPs) should continue to ollow
the current WHO recommendation to obtain sputum specimens or smear mi-
croscopy at the end o months 5 and 6 or all new pulmonary B patients who
were smear-positive at the start o treatment. Patients whose sputum smears are
positive at month 5 or 6 (or who are ound to harbour MDR-B strains at any
7/31/2019 A 110525 Meden Ttotg
18/150
7
time) will be re-registered as having ailed treatment and be treated according to
Recommendation 7 below.
L Recommendation 5.4
In previously treated patients, i the specimen obtained at the end o the inten-sive phase (month 3) is smear-positive, sputum culture and drug susceptibility
testing (DS) should be perormed
(Strong/High grade o evidence)
Qesti 6. Tetet etesi i ew p Tb ptiets
In new pulmonary B patients, how eective is extension o treatment or preventing
ailure or relapse?
L Recommendation 6
In patients treated with the regimen containing riampicin throughout treat-
ment, i a positive sputum smear is ound at completion o the intensive phase,
the extension o the intensive phase is not recommended
(Strong/High grade o evidence)
Remark: WHO recommends that a positive sputum smear at completion o the
intensive phase should trigger a careul review o the quality o patient support
and supervision, with prompt intervention i needed (see Chapter 4). It should alsotrigger additional sputum monitoring, as per Recommendations 5.2, 5.3 and 5.4.
Qesti 7. Pevis tete ptiets
Which (i any) groups o patients should receive a retreatment regimen with rst-line
drugs?
able 3.5 in Chapter 3 shows Recommendations 7.17.4.
L Recommendation 7.1
Specimens or culture and drug susceptibility testing (DS) should be obtainedrom all previously treated B patients at or beore the start o treatment. DS
should be perormed or at least isoniazid and riampicin
Remark a: DS may be carried out by rapid molecular-based methods or by con-
ventional methods. Sputum should be obtained, as well as appropriate specimens
or extrapulmonary B, depending on the site o disease.
Remark b: Obtaining specimens or culture and DS should not delay the start o
treatment. Empirical therapy should be started promptly, especially i the patient
is seriously ill or the disease is progressing rapidly.
ExECuTIVE Summary
7/31/2019 A 110525 Meden Ttotg
19/150
8
TrEaTmEnT o TubErCuloSIS: GuIdElInES
L Recommendation 7.2
In settings where rapid molecular-based DS is available, the results should
guide the choice o regimen
L Recommendation 7.3In settings where rapid molecular-based DS results are not routinely available
to guide the management o individual patients, empirical1 treatment should be
started as ollows:
L Recommendation 7.3.1
B patients whose treatment has failed2 or other patient groups with high
likelihood o multidrug-resistant B (MDR-B) should be started on an em-
pirical MDR regimen
Remark a: In the absence o culture and DS results, the patient should be clini-
cally evaluated beore the MDR regimen is administered.
Remark b: Other examples o patients with high likelihood o MDR-B are
those relapsing or deaulting aer their second or subsequent course o treat-
ment. See also section 3.8.2.
L Recommendation 7.3.2
B patients returning afer deaulting or relapsing rom their rst treat-
ment course may receive the retreatment regimen containing rst-line drugs
2HRZES/1HRZE/5HRE i country-specic data show low or medium levels
o MDR in these patients or i such data are unavailable
Remark: When DS results become available, regimens should be adjusted
appropriately.
L Recommendation 7.4
In settings where DS results are not yet routinely available to guide the man-
agement o individual patients, the empirical regimens will continue through-
out the course o treatmentL Recommendation 7.5
National B control programmes should obtain and use their country-specic
drug resistance data on ailure, relapse and deault patient groups to determine
the levels o MDR.
1 In these guidelines, empirical means providing treatment beore (or without) knowing whether the
patients B organisms are MDR or not.2 Failures in a well-run NP should be inrequent in the absence o MDR-B. I they do occur, they are
due either to MDR-B or to programme actors such as poor DO or poor drug quality. I drug resis-tance data rom ailure patients are avai lable and show low or medium levels o MDR, patients shouldreceive the retreatment regimen outlined in section 7.3.2., and every eort should be made to addressthe underlying programmatic issues.
7/31/2019 A 110525 Meden Ttotg
20/150
9
Remark: Country-specic drug resistance data should include data stratied by
type o regimen given or the patients rst course o B treatment (i.e. 2 vs 6
months o riampicin).
able B below lists key changes in this ourth edition, compared to the 2004 updateo the third edition.1
Tab B Key cHAngeS Since THe THird ediTion
Chapter 1. IntroduCtIon
Te scope is now limited to treatment o B in adults. Te ourth edition no longer
covers:
B case detection and diagnosis;
diagnosis and treatment o B in children (WHO has published a separateguideline on management o childhood B);
drug supply management.
Instead o Diagnostic categories IIV, this edition uses the same patient regis-
tration groups used or recording and reporting, which dierentiate new patients
rom those with prior treatment and speciy reasons or retreatment.
Each applicable standard rom the International Standards or B Care is cross-
reerenced.
An expiry date is provided.
Chapter 2. Case defInItIons
Te recent WHO case denition or sputum smear-positive pulmonary B2 has
been applied to a denite case o B, so that now a patient with one positive AFB
smear is considered a denite case in countries with a unctional external quality
assurance (EQA) system. (In the third edition, two positive smears were required
beore a patient could be considered a denite case.)
Bacteriology now includes culture and new methods or identication oM. tuber-culosis.
New WHO data elements or recording and reporting, such as HIV status and
MDR-B, are included.
Severity o disease is no longer included as a eature o the case denition.
In the denition or smear-negative B, this edition incorporates WHO policy
reducing the number o specimens rom three to two or screening patients sus-
pected to have B. Tis policy applies only in settings where a well-unctioning
EQA system exists, the workload is very high, and human resources are limited.3
1 http://www.who.int/tb/publications/cds_tb_2003_313/en/index.html2 http://www.who.int/tb/dots/laboratory/policy/en/index1.html3 http://www.who.int/tb/dots/laboratory/policy/en/index2.html
ExECuTIVE Summary
7/31/2019 A 110525 Meden Ttotg
21/150
10
TrEaTmEnT o TubErCuloSIS: GuIdElInES
In settings with an HIV prevalence >1% in pregnant women or 5% in B patients,
sputum culture or Mycobacterium tuberculosis should be perormed in patients
who are sputum smear-negative to conrm the diagnosis o B.
A trial o broad-spectrum antibiotics is no longer recommended to be used as adiagnostic aid or smear-negative pulmonary B in persons living with HIV.
For HIV-negative patients, the ourth edition species that, i broad-spectrum
antibiotics are used in the diagnosis o smear-negative pulmonary B, anti-B
drugs and fuoroquinolones should be avoided.
Pulmonary B cases without smear results are no longer classied as smear-
negative. Instead, they are labelled smear not done on the B register and in the
annual WHO survey o countries.
Consistent with Standard 3 o the International Standards or B Care, culture and
histopathological examination are recommended or specimens rom suspected
extrapulmonary sites o B. Examination o sputum and a chest radiograph are
also suggested, in case patients have concomitant pulmonary involvement.
Te patient registration group Other no longer includes chronic. Instead,
patients whose sputum is smear-positive at the end o (or returning rom) a sec-
ond or subsequent course o treatment are classied by the outcome o their most
recent retreatment course: relapsed, deaulted or ailed.
Chapter 3. standard treatment regImens
Additional dosage inormation is provided or isoniazid (maximum daily dose or
three times per week) and streptomycin (maximum dose, and adjustments in per-
sons aged over 60 years or weighing less than 50 kg). Tioacetazone is no longer
included among the rst-line drugs.
A new section on B patient kits has been added.
Te recommended new patient regimen contains 6 months o riampicin; the
regimen with 2 months o riampicin (with the 6-month continuation phase oisoniazid and ethambutol) is no longer an option.
In this edition, three times weekly dosing throughout therapy is an alternative only
or patients who are receiving directly observed therapy o every dose and who are
not HIV-positive or living in an HIV-prevalent setting. Tree times weekly dosing
during the intensive phase is no longer an option or HIV-positive B patients or
B patients living in HIV-prevalent settings.
WHO now recommends against twice weekly dosing or the ull course o treat-
ment or new patients (unless done in the context o ormal research).Te third
edition included the option to omit ethambutol during the intensive phase o
treatment or patients with non-cavitary, smear-negative pulmonary B or extra-
7/31/2019 A 110525 Meden Ttotg
22/150
11
pulmonary disease who are known to be HIV-negative. In the ourth edition, the
omission o ethambutol is no longer recommended.
Tis ourth edition includes an alternative continuation phase o ethambutol,
riampicin, and isoniazid or new patients in populations with high levels o isoni-azid resistance. Tis conditional recommendation applies where isoniazid suscep-
tibility testing in new patients is not done (or results are not available) beore the
continuation phase begins.
DS beore or at the start o therapy is strongly recommended or all previously
treated patients.
Previously treated patients are dened by their likelihood o MDR-B, and rec-
ommendations or treatment regimen depend on reason or retreatment (ailure,
versus relapse and deault).
Laboratory tests (liquid media, line probe assays) to meet the needs or the prompt
identication oM. tuberculosis and DS are discussed, based on country-specic,
comprehensive plans or laboratory strengthening.
Guidance or starting therapy is provided or previously treated patients, based
on whether the country has access to new rapid molecular-based tests, access to
conventional DS, or no routine access to DS results to guide management o
individual patients.
In countries using conventional DS, a standard empirical MDR regimen is rec-
ommended or patients with high likelihood o MDR, while awaiting DS results.
When DS results become available, regimens should be adjusted appropriately.
An MDR regimen is now recommended as one o each countrys standard regi-
mens, or use in conrmed MDR-B cases as well as in patients with a high likeli-
hood o MDR while awaiting DS results. Tis edition also gives interim guidance
to countries where DS is not yet routinely available or individual retreatment
patients.
Given the availability o unding rom international nancial mechanisms, lack o
resources or MDR treatment is no longer an acceptable rationale or providing a
retreatment regimen o rst-line drugs (ormerly called the Category 2 regimen)
to patients with a high likelihood o MDR.
Te previous edition recommended the 8-month retreatment regimen with rst-
line drugs or all B patients returning aer deaulting or relapsing. By contrast,
this edition allows or the possibility that, in some countries, these patients may
have levels o MDR-B that are high enough to warrant an MDR regimen whileawaiting results o DS.
WHO does not intend to establish thresholds or low, moderate, or high likeli-
hoods or levels o MDR. NPs will dene low, moderate and high or their
ExECuTIVE Summary
7/31/2019 A 110525 Meden Ttotg
23/150
12
TrEaTmEnT o TubErCuloSIS: GuIdElInES
own countries, based on levels o MDR in specic patient groups, as well as other
actors such as MDR treatment resources available during scale-up, and requency
o concomitant conditions (such as HIV) that increase the short-term risk o dying
rom MDR-B. Country drug resistance surveys, WHO estimates o MDR levels, and other data
sources are recommended to inorm decisions on each countrys standard treat-
ment regimens or dened patient groups.
Intermittent dosing is no longer an option or previously treated patients receiving
the 8-month retreatment regimen with rst-line drugs.
Chapter 4. monItorIng durIng treatment
Te perormance o sputum smear microscopy at the completion o the inten-
sive phase o treatment is a conditional, rather than a strong, recommendation,
given the evidence that a positive smear at this stage has a very poor ability to pre-
dict relapse or pretreatment isoniazid resistance (Annex 2). However, its utility in
detecting problems with patient supervision and or monitoring programme per-
ormance is rearmed.
In addition, this edition recommends that a positive sputum smear at the end o
the intensive phase in new patients should trigger sputum smear microscopy at
the end o the third month. I the latter is positive, culture and DS should be
perormed.
Tis edition no longer recommends extension o the intensive phase or patients
who have a positive sputum smear at the end o the second month o treatment.
In previously treated patients, i the specimen obtained at the end o the intensive
phase (month 3) is smear-positive, this edition recommends that sputum culture
and DS be perormed then, rather than waiting until month 5 (which was recom-
mended in the third edition).
Te outcome o cure now encompasses culture results. Patients ound to harbour an MDR-B strain at any point during treatment are
now classied as treatment ailure. Tey are re-registered and begin an MDR
regimen.
For MDR-B patients, this edition recommends the use o the MDR-B register
and cohort analysis.
Te symptom-based approach to side-eects o anti-B drugs has been revised.
7/31/2019 A 110525 Meden Ttotg
24/150
13
Chapter 5. Co-management of hIV and aCtIVe tB dIsease
Provider-initiated HIV testing or all patients with known or suspected B is now
recommended, regardless o the stage o the countrys HIV epidemic.
Tis edition includes current WHO recommendations to start co-trimoxazole as
soon as possible when a person living with HIV is diagnosed with B.
Daily dosing is strongly recommended during the intensive phase or B patients
with known positive HIV status, and all new patients living in HIV-prevalent
settings. Tree times per week dosing during the intensive phase is no longer an
acceptable alternative.
Current WHO recommendations or antiretroviral therapy and timing o initia-
tion are incorporated. Drug susceptibility testing is now recommended at the start o B therapy in all
people living with HIV.
Chapter 6. superVIsIon and patIent support
Roles o the patient, B programme sta, the community, and other providers
are described in assuring adherence to treatment. A treatment supporter must be
identied or each B patient, which may be a health worker, or a trained and
supervised member o the community or amily.
reatment supervision is dened in the context o a larger support package to
address patients needs.
Chapter 7. treatment of drug-resIstant tB
Tis chapter has been extensively revised to refect recent WHO recommendations
or the programmatic management o drug-resistant B.
Chapter 8. tB treatment of extrapulmonary dIsease and of tB In
speCIal sItuatIons
While WHO continues to recommend the same regimens or extrapulmonaryand pulmonary disease, this ourth edition reerences other guidelines suggesting
longer treatment or B meningitis and or bone or joint B.
For B patients with pre-existing liver disease, this ourth edition includes regi-
mens with one, two and no hepatotoxic drugs. A 9-month regimen o riampicin
and ethambutol is no longer included as an option.
For B patients with renal ailure, this edition recommends the 6-month regimen
with isoniazid, riampicin, ethambutol and pyrazinamide, whereas the prior edi-
tion omitted pyrazinamide. Tis edition recommends administering ethambutol(15 mg/kg) and pyrazinamide (25 mg/kg) three times per week. Tis edition now
discourages the use o streptomycin in patients with renal ailure; however, i it
must be used, 15 mg/kg should be administered two to three times per week, with
monitoring o drug levels.
ExECuTIVE Summary
7/31/2019 A 110525 Meden Ttotg
25/150
14
TrEaTmEnT o TubErCuloSIS: GuIdElInES
annexes
ae 1
Riampicin: includes a list o drugs which interact with riampicin. Streptomycin: dosage adjustments or the elderly and adults weighing less than
50 kg are provided.
Ethambutol: creatinine clearance
7/31/2019 A 110525 Meden Ttotg
26/150
15
1
itrocto
1.1 Chpte jectives
Tis chapter denes the purpose, target audience, scope and development o this
ourth edition o the guidelines. It also explains why a new edition was needed and
projects a date or the next revision.
1.2 Ppse the gieiesTe principal purpose o these guidelines is to help national B control programmes
(NPs) in setting B treatment policy to optimize patient cure: curing patients will
prevent death, relapse, acquired drug resistance, and the spread o B in the commu-
nity. Teir urther purpose is to guide clinicians working in both public and private
sectors.
1.3 Tget iece
Te primary target audience or the guidelines is the managers and sta o NPs,
together with other B service providers working in public and private health care
acilities at the central and peripheral levels.
Use o the term NP manager in these guidelines reers to the ocial within, or
designated by, the ministry o health who is responsible or the B programme or to
that ocials designee.
1.4 Scpe
Tese guidelines address the treatment o active B disease in adults. Tey exclude
many related topics that have already been covered in detail in other publications:
diagnosis, laboratory standards or smear microscopy, protocols or use o rapid drug
susceptibility tests, paediatric B, drug procurement and supply management, in-
ection control, intensied case-nding in persons living with HIV, and isoniazid
preventive therapy.
1.5 Wh ew eiti?
Major progress in global B control ollowed the widespread implementation o the
DOS strategy. Te Stop B Strategy, launched in 2006, builds upon and enhancesthe achievements o DOS (1): new objectives include universal access to patient-
centred treatment, and protection o populations rom B/HIV coinection and
multidrug-resistant B (MDR-B). Te Stop B Strategy and the Global Plan (2) to
7/31/2019 A 110525 Meden Ttotg
27/150
16
TrEaTmEnT o TubErCuloSIS: GuIdElInES
implement the new strategy made it necessary to revise the existing guidelines (3)
and develop this ourth edition.
Historically, the greatest emphasis o B control activities has been on the most in-
ectious patients those who have sputum smear-positive pulmonary tuberculosis(3). Tis changed with the Stop B Strategys emphasis on universal access or all
persons with B to high-quality, patient-centred treatment (1). However, highly in-
ectious, smear-positive patients remain the primary ocus or other aspects o B
control, including contact tracing and inection control. Te Patients Charter or B
Care species that all B patients have the right to ree and equitable access to B
care, rom diagnosis through treatment completion (4).
Tis ourth edition o the guidelines has thereore abandoned Categories IIV, which
were used to prioritize patients or treatment.1
According to this prior categorization,smear-negative B patients were assigned third priority and MDR-B patients ourth
priority. For treatment decisions it no longer makes sense to assign third priority
to smear-negative patients given their high mortality i they are living with HIV.
Equally, MDR-B patients should not be assigned ourth priority, given their high
mortality and the urgent need to prevent the spread o these deadliest B strains.
o replace Categories IIV, this ourth edition groups patients (and standard regi-
mens recommended or each group) according to the likelihood o their having
drug resistance. Drug resistance is a critical determinant o treatment success, and
prior B treatment coners an increased risk (5, 6). Tis edition uses the same patient
registration groups as those used or recording and reporting, which dierentiate
new patients rom those who have had prior treatment (7). Registration groups or
previously treated patients are based on the outcome o their prior treatment course:
ailure, relapse, and deault.
Te ourth edition integrates detection and treatment o both HIV inection and
MDR-B, and thus should contribute towards achievement o the Stop B Strategys
universal access to high-quality MDR-B and HIV care.
With regard to HIV detection, this edition incorporates recent WHO recommenda-
tions or provider-initiated HIV testing o all persons with diagnosed or suspected
B, in all types o HIV epidemics (low-level, concentrated or generalized) (8). For
treatment o B in persons living with HIV, new recommendations on the dura-
tion o therapy and the role o intermittent regimens have emerged rom systematic
reviews (see Chapter 5). Te new edition also includes recent WHO recommenda-
tions or DS at the start o B therapy in all people living with HIV (9), as well as
recommendations on the timing and type o antiretroviral therapy (AR) regimens
(10).1 Also, the original one-to-one correspondence between patient group and treatment regimens was lost
as Categories IIV were redened over the years. Te same treatment regimen came to be recommend-ed or patients in Categories I and III; aer 2004, dierent treatment regimens were recommended orpatients in Category II depending on actors such as programme perormance and drug resistance.
7/31/2019 A 110525 Meden Ttotg
28/150
17
New developments in MDR-B also contributed to the need or this revision. Build-
ing on the principle o universal access to MDR-B diagnosis and care, Te MDR-B
and XDR-B response plan 20072008 (11) calls or the diagnosis and treatment o
MDR-B in all countries by 2015. Even countries with low overall levels o multidrugresistance (MDR) are aced with B patients who have been previously treated a
group that is ve times more likely to have MDR-B than new patients (see section
3.6).
In terms o ensuring universal access to MDR-B diagnosis, this ourth edition rea-
rms existing WHO recommendations (2) that all previously treated patients should
have access to culture and DS at the beginning o treatment, in order to identiy
MDR-B as early as possible.1 It also incorporates the WHO recommendation that
treatment ailure be conrmed by culture and DS (9). In order to detect MDR soon-
er than the end o the h month o treatment, this edition includes the existing
WHO recommendation (9) or culture and DS i patients still have smear-positive
sputum at the end o the third month o treatment.
Chapters 25 o this new edition discuss the critical role o the identication oMyco-
bacterium tuberculosis and o DS. Tis is in contrast to the previous edition, which
relied almost exclusively on smear microscopy or case denition, assignment o stand-
ard regimens, and monitoring o treatment response. Line probe assays can identiy
MDR-B within hours and liquid media can do so within weeks (rather than months
when solid media are used) (12). Tese techniques should be introduced in line withcomprehensive, country-specic plans or laboratory capacity strengthening.
o move towards universal access to MDR-B treatment, the ourth edition includes
a new recommendation or every country to include an MDR regimen in its stand-
ard regimens. Tis is essential while awaiting DS results or patients with a high
likelihood o MDR (such as those whose prior treatment with a 6-month riampicin
regimen has ailed), and or patients in whom resistance to isoniazid and riampicin is
conrmed. With the availability o unding rom international nancial partners,2 lack
o resources or MDR-B treatment is no longer an acceptable rationale or providingthe 8-month retreatment regimen with rst-line drugs (ormerly called the Category
II regimen) to patients with a high likelihood o MDR; this regimen is ineective in
treating MDR-B and may result in amplication o drug resistance (5, 13).
Use o rapid DS methods will eventually render the 8-month retreatment regimen
o rst-line drugs obsolete. In the meantime, the regimen is retained in this ourth
edition in only two circumstances. In countries with access to routine DS using
conventional methods, the 8-month retreatment regimen with rst-line drugs is
recommended while awaiting DS results rom patients who have relapsed or are
returning aer deault (i country-specic data show they have a medium likelihood
1 Tis recommendation is consistent with the International Standards or uberculosis Care and resolu-tions endorsed by the World Health Assembly in 2007 which call or universal access to DS by 2015.
2 Such as UNIAID and the Global Fund to Fight AIDS, uberculosis and Malaria.
1. InTroduCTIon
7/31/2019 A 110525 Meden Ttotg
29/150
18
TrEaTmEnT o TubErCuloSIS: GuIdElInES
o MDR-B, or i such data are unavailable). In countries that do not yet have DS
routinely available at the start o treatment or all previously treated patients (see sec-
tion 3.7.3), the 8-month retreatment regimen with rst-line drugs will be used or the
duration o treatment on an interim basis until laboratory capacity is available.In principle, MDR treatment should be introduced only in well-perorming DOS
programmes. Beore ocusing on curing MDR-B cases, it is critical to turn o the
tap, i.e. to strengthen poor programmes so that they stop giving rise to MDR-B.
Following this principle, the 2004 revision o the treatment chapter1 listed adequate
perormance o a countrys overall B programme as a requirement or the use o
MDR regimens in patients with a high likelihood o MDR. Tis is no longer a pre-
requisite in the ourth edition. In some countries with limited DOS coverage, there
may be an appropriate setting or an MDR pilot project that, once established, can
provide a model and an impetus or the expansion o basic DOS into more areas.
In most countries, however, conditions or initiating an MDR component in most
NPs are not met until the overall NP has the essential elements o DOS rmly
in place.
1.6 methg
Development o the ourth edition o the guidelines ollowed new WHO procedures.
WHO dened the scope o revision and convened a guidelines group o external
experts. All members o the group completed a Declaration or the Confict o Inter-est; there were no conficts declared. With input rom the Guidelines Group, WHO
identied seven key questions on the treatment o B (see Annex 2) covering the
ollowing topics:
duration o riampicin in new patients;
dosing requency in new patients;
initial regimen or new B patients in countries with high levels o isoniazid
resistance;
B treatment in persons living with HIV; sputum monitoring during B treatment;
treatment extension;
retreatment.
Systematic literature reviews were conducted or each question and the evidence was
synthesized2 (see Annex 2).
Input rom the Guidelines Group to the revision o guidelines was made by e-mail, in
conerence calls and at a 3-day meeting (2123 October 2008) during which the nal
treatment recommendations were established once consensus had been reached by1 reatment o tuberculosis: guidelines or national programmes, 3rd ed. Chapter 4, Standard treatment
regimens, was revised in June 2004 and the new version was posted on the WHO web site.2 At the time o publication o this ourth edition, evidence gathered through some o the systematic
reviews had not been published.
7/31/2019 A 110525 Meden Ttotg
30/150
19
the Guidelines Group. Te recommendations are based on the quality o the evidence,
values, and costs, as well as judgements about trade-os between benets and harm.
Te group graded the strength o each recommendation, refecting the degree o con-
dence that the desirable eects o adherence to a recommendation outweigh theundesirable eects. Although the degree o condence is necessarily a continuum,
three categories are used strong, conditional and weak. Te quality o the evidence
was assessed according to the GRADE methodology (14).
Moderate/low quality o evidence means that the estimate o eect o the interven-
tion is very uncertain and urther research is likely to have an important impact on
condence in the estimate. For high-quality evidence, by contrast, urther research
is unlikely to change condence in the estimate o eect.
A strong recommendation means that the desirable eects o adherence to the rec-ommendation clearly outweigh the undesirable eects. Strong recommendations use
the words should or should not. No alternatives are listed.
A conditional recommendation means that the desirable eects o adherence to the
recommendation probably outweigh the undesirable eects, but the trade-os are
uncertain. Reasons or lack o certainty include:
high-quality evidence to support the recommendation is lacking;
benets o implementing the recommendation are small;
benets may not justiy the costs;
it was not possible to arrive at precise estimates o benet.
A weak recommendation means that there is insucient evidence; the recommenda-
tion is thereore based on eld application and expert opinion.
Conditional and weak recommendations use the word may. Alternatives are listed
or several o the conditional recommendations.
able 1.1 shows how strong and conditional recommendations dier in terms both
o wording and o the actors used to judge their strength. Strong and conditionalrecommendations also have dierent implications or policy-makers, patients, and
health care providers; these are summarized in the table.
A plan or implementing and evaluating the strong recommendations is outlined in
Annex 4. o address the gaps in the evidence critical or decision-making, the Guide-
lines Group developed a series o questions as a basis or uture research; these are
detailed in Annex 5. Members o the Guidelines Group are listed in Annex 6.
Te recommendations that address the seven key questions appear in the context
o guidance on standard treatment (Chapter 3), monitoring (Chapter 4) and HIV(Chapter 5). Areas outside the scope o those questions have been updated with cur-
rent reerences and WHO B policies but were not the subject o systematic literature
reviews or o new recommendations by the Guidelines Group.
1. InTroduCTIon
7/31/2019 A 110525 Meden Ttotg
31/150
20
TrEaTmEnT o TubErCuloSIS: GuIdElInES
Tab 1.1 STrong VerSuS condiTionAl recommendATionS
receti s tegth
Stg Citi
Phsig theeceti
Sh sh t.n atatvs a st
opti is, , itis (t) ecee.Atatvs a t st
cts se t jge stegth
qat v Hh-at v l-at v
Baa btsab a sab
ts att ab hath
la, ta t bt a/ bt bts a
has bs
Sa a/ taat
rs aat l st ( t t tatabt hth th tvtsts a s s
ss)
Hh st ( hhtat)
utat vas a
s; vaabtass atts
Sa at tat
vaabt
la at tat
vaabt
Ipictis
pic-kes
( nTpaas)
Th at sh
va b s stt
p-ak
tsv bat
ptiets mst vas at th s at
Th s at a b ajst th bass asbt a
atabt heth ce
pviesmst atts sh b tat
a t th s at. Ah
t ths at s aasab as
at a
7/31/2019 A 110525 Meden Ttotg
32/150
21
Te dra guidelines were circulated to the external review group (whose members
are listed in Annex 6), made up o NP managers rom high-burden countries, mem-
bers o the WHO Strategic, echnical and Advisory Group on B (SAG-B), six
regional B Advisers and B medical ocers working in high-burden countries.Comments received rom the external review group were appropriately addressed
and the ew disagreements between the external reviewers and the Guidelines Group
were resolved by e-mail consultation.
1.7 Iteti Sts Tecsis Ce
Te International Standards or uberculosis Care (ISC) (15) describe a widely ac-
cepted level o B care that all practitioners should seek to achieve. Cross-reerencing
the applicable ISC standards in this new edition should help providers in both pub-lic and private sectors to ensure their implementation.
1.8 Epi te
Te WHO Stop B Department will review and update these guidelines aer 35
years or as needed when new evidence, treatment regimens or diagnostic tests
become available.
reeecesRaviglione MC, Uplekar MW. WHOs new stop B strategy.1. Lancet, 2006, 367:952
955.
Te global plan to stop B, 200620152. . Geneva, World Health Organization, 2006
(WHO/HM/SB/2006.35).
reatment o tuberculosis: guidelines or national programmes3. , 3rd ed. Geneva, World
Health Organization, 2003 (WHO/CDS/B/2003.313).
Patients charter or tuberculosis care: patients rights and responsibilities4. . Geneva,
World Care Council, 2006 (available at: www.who.int/tb/publications/2006/patients_
charter.pd).
Espinal MA et al. Standard short-course chemotherapy or drug-resistant tuberculo-5.sis: treatment outcomes in 6 countries.Journal o the American Medical Association,
2000, 283:25372545.
Aziz MA et al. Epidemiology o antituberculosis drug resistance (the Global Project6.
on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet,
2006, 368:21422154.
Revised B recording and reporting orms and registers version 20067. . Geneva, World
Health Organization, 2006 (WHO/HM/B/2006.373; available at: www.who.int/
tb/dots/r_and_r_orms/en/index.html).
Guidance on provider-initiated HIV testing and counselling in health acilities8. .Geneva, World Health Organization, 2007.
Guidelines or the programmatic management o drug-resistant tuberculosis: emer-9.
gency update 2008. Geneva, World Health Organization, 2008 (WHO/HM/B/
2008.402).
1. InTroduCTIon
7/31/2019 A 110525 Meden Ttotg
33/150
22
TrEaTmEnT o TubErCuloSIS: GuIdElInES
Antiretroviral therapy or HIV inection in adults and adolescents in resource-limited10.
settings: recommendations or a public health approach. Geneva, World Health Or-
ganization, 2006.
Te global MDR-B & XDR-B response plan 2007200811. . Geneva, World Health Or-
ganization, 2007 (WHO/HM/B/2007.387).
Molecular line probe assays or rapid screening o patients at risk o MDR B: policy12.
statement. Geneva, World Health Organization, 2008 (available at: www.who.int/tb/
eatures_archive/policy_statement.pd).
Espinal MA. ime to abandon the standard retreatment regimen with rst-line13.
drugs or ailures o standard treatment. International Journal o uberculosis and
Lung Disease, 2003, 7:607608.
Guyatt GH et al. GRADE: an emerging consensus on rating quality o evidence and14.
strength o recommendations. British Medical Journal, 2008, 336:924926.
International Standards or uberculosis Care (ISC)15. , 2nd ed. Te Hague, uberculo-sis Coalition or echnical Assistance, 2009.
7/31/2019 A 110525 Meden Ttotg
34/150
23
2
Ca fto
2.1 Chpte jectives
Tis chapter describes
the purpose o having case denitions or tuberculosis;
the denition o a case o B, as well as o suspected and conrmed cases;
additional eatures o B cases important or the treatment o individual pa-
tients, as well as or evaluating B programmes and monitoring the epidemic.Te diagnosis o B reers to the recognition by health workers (medical ocer,
nurse, paramedic or other) o an active case, i.e. a patient with current disease due to
M. tuberculosis. Te role o NPs is dierent: they are responsible or ensuring that
diagnosed cases are notied (1), meet the denition or case or denite case, and are
treated appropriately, and that outcomes are evaluated.1
All providers must report both new and retreatment B cases and their treatment
outcomes to local public health authorities, in conormance with applicable legal re-
quirements (Standard 21 o the ISC (5)). NPs ensure that critical eatures o the Bcase are recorded and reported so that treatment is appropriate and eedback is pro-
vided to the treating clinician (6). Analysis o these reports also helps the NP man-
ager to monitor trends and evaluate the eectiveness o B activities at all levels.
2.2 Ppses efig Tb cse
Uniorm criteria to dene a B case are needed or:
proper patient registration and case notication;
selecting appropriate standard treatment regimens (see Chapter 3); standardizing the process o data collection or B control;
evaluating the proportion o cases according to site, bacteriology and treat-
ment history;
cohort analysis o treatment outcomes;
accurate monitoring o trends and evaluation o the eectiveness o B pro-
grammes within and across districts, countries and global regions.
2.3 Cse efitis
Te B case denitions below are based on the level o certainty o the diagnosis and
on whether or not laboratory conrmation is available.
1 NP programmes also acilitate the detection o cases via sputum screening o suspects with coughattending health acilities (2), as well as screening o contacts (3) and screening o persons living withHIV/AIDS (4).
7/31/2019 A 110525 Meden Ttotg
35/150
24
TrEaTmEnT o TubErCuloSIS: GuIdElInES
uberculosis suspect. Any person who presents with symptoms or signs sugges-
tive o B. Te most common symptom o pulmonary B is a productive cough or
more than 2 weeks,1 which may be accompanied by other respiratory symptoms
(shortness o breath, chest pains, haemoptysis) and/or constitutional symptoms(loss o appetite, weight loss, ever, night sweats, and atigue).2
Case o tuberculosis. A denite case o B (dened below) or one in which a
health worker (clinician or other medical practitioner) has diagnosed B and has
decided to treat the patient with a ull course o B treatment.
Note. Any person given treatment or B should be recorded as a case. Incomplete
trial B treatment should not be given as a method or diagnosis.
Denite case o tuberculosis. A patient withMycobacterium tuberculosis complex
identied rom a clinical specimen, either by culture or by a newer method suchas molecular line probe assay. In countries that lack the laboratory capacity to
routinely identiyM. tuberculosis, a pulmonary case with one or more initial spu-
tum smear examinations positive or acid-ast bacilli (AFB) is also considered to
be a denite case, provided that there is a unctional external quality assurance
(EQA) system with blind rechecking.3
Cases o B are also classied according to the:
anatomical site o disease;
bacteriological results (including drug resistance);
history o previous treatment;
HIV status o the patient.
Each o these key eatures o B cases is discussed below.
2.4 atic site Tb isese
In general, recommended treatment regimens are similar, irrespective o site (see sec-
tion 8.2). Dening the site is important or recording and reporting purposes and to
identiy the more inectious patients those with pulmonary involvement (who will
be urther subdivided by smear status see section 2.5 below).
Pulmonary tuberculosis (PB) reers to a case o B (dened above) involving the
lung parenchyma. Miliary tuberculosis is classied as pulmonary B because there
are lesions in the lungs. uberculous intrathoracic lymphadenopathy (mediastinal
and/or hilar) or tuberculous pleural eusion, without radiographic abnormalities in
the lungs, constitutes a case oextrapulmonary B. A patient with both pulmonary
and extrapulmonary B should be classied as a case opulmonary B.
1 Standard 1 o the International Standards or B Care (5) states that all persons with otherwise unex-plained productive cough lasting 23 weeks or more should be evaluated or B.
2 Te denition o a B suspect depends on other local actors, including the patients age and HIVstatus, HIV prevalence in the population, B prevalence in the population, etc.
3 See: www.who.int/tb/dots/laboratory/policy/en/index1.html.
7/31/2019 A 110525 Meden Ttotg
36/150
7/31/2019 A 110525 Meden Ttotg
37/150
26
TrEaTmEnT o TubErCuloSIS: GuIdElInES
Smear-negative PB cases should either:
A. have sputum that is smear-negative but culture-positive orM. tuberculosis:
a case o pulmonary B is considered to be smear-negative i at least two
sputum specimens at the start o treatment are negative or AFB1 in countries
with a unctional EQA system, where the workload is very high and human
resources are limited (see http:///www.who.int/tb/dots/laboratory/policy/en/
index2.html);
in all settings with an HIV prevalence o >1% in pregnant women or 5% in B
patients, sputum culture or M. tuberculosis should be perormed in patients
who are sputum smear-negative to conrm the diagnosis o B (4).
ORB. meet the ollowing diagnostic criteria: (68)
decision by a clinician to treat with a ull course o anti-B therapy; and
radiographic abnormalities consistent with active pulmonary B and
either:
laboratory or strong clinical evidence o HIV inection
or:
i HIV-negative (or unknown HIV status living in an area o low HIV preva-lence), no improvement in response to a course o broad-spectrum antibiot-
ics (excluding anti-B drugs and fuoroquinolones and aminoglycosides).
Pulmonary B cases without smear results are no longer classied as smear-negative
(4); instead, they are recorded as smear not done on the B register (6) and on the
annual WHO survey o countries.
For patients suspected o having EPB, specimens should be obtained rom the sus-
pected sites o involvement (Standard 3 o the ISC (5)). Where available, culture
and histopathological examination should also be carried out. Additionally, a chest
X-ray and examination o sputum may be useul, especially in persons with HIV
inection.
2.6 Hist pevis tetet: ptiet egistti gp
At the time o registration, each patient meeting the case denition is also classied
according to whether or not he or she has previously received B treatment and, i so,
the outcome (i known). It is important to identiy previously treated patients because
they are at increased risk o drug resistance, including MDR-B (see section 3.6).At the start o therapy, specimens should be obtained or culture and DS rom all
previously treated patients. reatment depends on whether the patient has relapsed
1 And no specimen is smear-positive.
7/31/2019 A 110525 Meden Ttotg
38/150
27
or is returning aer deault or aer prior treatment has ailed (see section 3.7). Te
distinctions between new and previously treated patients, and among the subgroups
o previously treated patients, are also essential or monitoring the B epidemic and
programme perormance.New patients have never had treatment or B, or have taken anti-B drugs or less
than 1 month. New patients may have positive or negative bacteriology and may have
disease at any anatomical site.
Previously treated patients have received 1 month or more o anti-B drugs in the
past, may have positive or negative bacteriology and may have disease at any ana-
tomical site. Tey are urther classied by the outcome o their most recent course o
treatment as shown in able 2.1 below.
Patients whose sputum is smear-positive at the end o (or returning rom) a secondor subsequent course o treatment are no longer dened as chronic. Instead, they
should be classied by the outcome o their most recent retreatment course: relapsed,
deaulted or ailed.
2. CaSE dEInITIonS
Tab 2.1 regiSTrATion group By ouTcome o moST recenT
TB TreATmenT
registti gp(a st sas)
bcteig otce st ecet pi tetet(efe i Te 4.1)
new +
Pevis tete repse + c
Tatt t
ie + Tatt a
det + dat
Tse i: A att h hasb tas ath TB
st t t tatt
+ St tatt
othe + A ass that t t th abvts, sh as atts
h t s t k hthth hav b vs tat;
h vs tat bt th
k t that vstattb (3, 8); a/
h hav t t tattth sa-atv pTB bata atv epTBb (3)
a + ats stv sa, t th as t M. tuberculosis
ats that a ss tst atv.b d as th tatt th wHo ts t abv.
7/31/2019 A 110525 Meden Ttotg
39/150
28
TrEaTmEnT o TubErCuloSIS: GuIdElInES
2.7 HIV stts
Determining and recording the patients HIV status is critical or treatment decisions
(see Chapters 3 and 5) as well as or monitoring trends and assessing programme
perormance. WHOs revised B reatment Card and B Register include dates oHIV testing, starting co-trimoxazole, and starting AR. Tese important interven-
tions are discussed more ully in Chapter 5.
reeeces
Engaging all health care providers in B control: guidance on implementing public-1.
private mix approaches. Geneva, World Health Organization, 2006 (WHO/HM/
B/2006.360).
WHO policy on B inection control in health care acilities, congregate settings and2.
households. Geneva, World Health Organization, 2009 (WHO/HM/B/2009.419).Implementing the WHO Stop B Strategy: a handbook or national tuberculosis control3.
programmes. Geneva, World Health Organization, 2008 (WHO/HM/B/2008.40).
Improving the diagnosis and treatment o smear-negative pulmonary and extrapulmo-4.
nary tuberculosis among adults and adolescents: recommendations or HIV-prevalent
and resource-constrained settings. Geneva, World Health Organization, 2007 (WHO/
HM/B/2007.379; WHO/HIV/2007.1).
International Standards or uberculosis Care (ISC)5. , 2nd ed. Te Hague, uberculo-
sis Coalition or echnical Assistance, 2009.
Revised B recording and reporting orms and registers version 20066. . Geneva, WorldHealth Organization, 2006 (WHO/HM/B/2006.373; available at: www.who.int/
tb/dots/r_and_r_orms/en/index.html).
Guidelines or the programmatic management o drug-resistant tuberculosis: emer-7.
gency update 2008. Geneva, World Health Organization, 2008 (WHO/HM/B/
2008.402).
Global tuberculosis control 2009: epidemiology, strategy, nancing. WHO report 20098. .
Geneva, World Health Organization, 2009 (WHO/HM/B/2009.411).
7/31/2019 A 110525 Meden Ttotg
40/150
29
3
staar tratmt rgm
3.1 Chpte jectives
Tis chapter describes:
the aims o treatment;
the recommended doses o rst-line anti-B drugs or adults;
regimens or new and previously treated patients;
considerations in selecting regimens or dened patient groups; evidence base or the selected regimens in dened patient groups.
Te choice o B regimens in special situations (pregnancy, concurrent use o oral
contraceptives, liver disease, and renal ailure) is covered in Chapter 8; B treatment
or persons living with HIV is discussed in Chapter 5.
3.2 ais tetet
Te aims o treatment o tuberculosis are:
to cure the patient and restore quality o lie and productivity;
to prevent death rom active B or its late eects;
to prevent relapse o B;
to reduce transmission o B to others;
to prevent the development and transmission o drug resistance.
3.3 Esseti titecsis gs
able 3.1 shows the essential anti-B drugs and their recommended dosages based
on the patients weight.
Te WHO-recommended ormulations o anti-B drugs and xed-dose combina-
tions (FDCs) o drugs appear in the WHO Model List o Essential Medicines (available
at www.who.int/medicines/publications/essentialmedicines/en). Te ormulations
and combinations o anti-B drugs available in each country should conorm to this
list. (See also the WHO Model Formulary at www.who.int/selection_medicines/list/
en.)
o acilitate procurement, distribution and administration o treatment to patients,
the daily dosage may be standardized or three or our body weight bands orinstance 3039 kg, 4054 kg, 5570 kg and over 70 kg, as is done with the Global
Drug Facility patient kits. (See also reerence 1.)
7/31/2019 A 110525 Meden Ttotg
41/150
30
TrEaTmEnT o TubErCuloSIS: GuIdElInES
All anti-B drugs should be quality-assured, and management o anti-B drugs
should be incorporated into the management o other essential medicines by the
ministry o health.Annex 1 provides additional inormation on the essential anti-B drugs, including
contraindications, precautions, use in pregnancy, adverse eects, and drug inter-
actions. Intermittent dosing schedules are discussed in section 3.5.1 below.
3.3.1 -s bats at-TB s
While evidence on xed-dose combinations (FDCs) o anti-B drugs was not system-
atically reviewed or this ourth edition, WHO continues to recommend their use,
as does Standard 8 o the ISC (3). FDCs are thought to prevent acquisition o drugresistance due to monotherapy, which may occur with separate (loose) drugs. With
FDCs, patients cannot be selective in the choice o drugs to ingest. Prescription errors
are likely to be less requent because dosage recommendations are more straightor-
ward, and adjustment o dosage according to patient weight is easier. Te number o
tablets to ingest is smaller and may thus encourage patient adherence.
While there is ecological evidence o the benets o FDCs in relation to drug re-
sistance in early studies o DOS programmes, there is limited direct evidence o
improved adherence with FDCs (4). A recent multicentre trial ound FDCs to have
equivalent ecacy to single pills and to be more acceptable to patients (5). However,
assessment o cure and relapses was based on smear microscopy and not on culture.
A multicentre trial (Te Union Study C) evaluating the ecacy, acceptability and
toxicity o a our-drug FDC compared with loose pills given in the intensive phase
Tab 3.1 recommended doSeS o irST-line AnTiTuBerculoSiS drugS
or AdulTS
dg
recee se
di 3 ties pe week
dse ge(/k b
ht)
mi()
dse ge(/k b
ht)
di i()
isaz 5 (46) 300 10 (812) 900
ra 10 (812) 600 10 (812) 600
paza 25 (2030) 35 (3040)
ethabt 15 (1520) 30 (2535)
Stta
15 (1218) 15 (1218) 1000a patts a v 60 as a t b ab t tat tha 500750 a, s s -
s t th s t 10 /k a atts ths a (2). patts
h ss tha 50 k a t tat ss abv 500750 a (WHO Model Formulary 2008,
.h.t/st_s/st//).
7/31/2019 A 110525 Meden Ttotg
42/150
31
3. STandard TrEaTmEnT rEGImEnS
o treatment has just been completed and results should soon be available. Another
multicentre study including pharmacokinetic assessment is soon to be completed by
WHO/DR.
Quality assurance is essential to ensure adequate bioavailability o the compo-nent drugs o FDCs.1 Using FDCs does not obviate the need or separate drugs or
patients who develop drug toxicity or intolerance or or those with contraindications
to specic component drugs.
3.3.2 patt kts
A B patient kit contains the ull course o treatment or a single patient and thus as-
sures the B patient that his or her medicines will be available throughout treatment.
Te kit provides health workers with a container that has all required medicines inthe necessary strengths and quantities. Tis helps limit conusion and wastage, and
makes it easier to monitor the regularity o treatment; avoiding stock-outs also helps
to maintain patient condence in the health system. In addition, the patient may eel
a sense o ownership o the patient kit and enhanced motivation to complete the
ull course o treatment during visits to the health centre he or she can actually see
the quantity o medicines that must be taken to achieve cure (1).
It should be noted that the B patient kit does not eliminate the need or directly
observed treatment (DO).
3.4 St egies efe ptiet gps
Standardized treatment means that all patients in a dened group receive the same
treatment regimen. Standard regimens have the ollowing advantages over individu-
alized prescription o drugs:
errors in prescription and thus the risk o development o drug resistance
are reduced;
estimating drug needs, purchasing, distribution and monitoring are acilitat-
ed;
sta training is acilitated;
costs are reduced;
maintaining a regular drug supply when patients move rom one area to an-
other is made easier;
outcome evaluation is convenient and results are comparable.
For assigning standard regimens, patients are grouped by the same patient regis-
tration groups used or recording and reporting, which dierentiate new patients
rom those who have had prior treatment. Registration groups or previously treatedpatients are based on the outcome o their prior treatment course: ailure, relapse and
deault (seeChapter 2).
1 See Global Drug Facil ity, www.stoptb.org/gd/drugsupply/quality_sourcing_process.asp.
7/31/2019 A 110525 Meden Ttotg
43/150
32
TrEaTmEnT o TubErCuloSIS: GuIdElInES
Recommended regimens or dierent patient registration groups are shown in ables
3.2, 3.3 and 3.4. More details on the evidence and judgements underlying the recom-
mended regimens are described in Annex 2.
3.5 new ptiets
New patients are dened as those who have no history o prior B treatment or who
received less than 1 month o anti-B drugs (regardless o whether their smear or
culture results are positive or not) (see section 2.6).
3.5.1 n atts s k t hav -sstb TB
New patients are presumed to have drug-susceptible B with two exceptions:
Where there is a high prevalence o isoniazid resistance in new patients (see sec-tion 3.5.2).
or
I they have developed active B aer known contact with a patient documented
to have drug-resistant B; they are likely to have a similar drug resistance pattern
to the source case (6), and DS should be carried out at the start o treatment.
While DS results o the patient are awaited, a regimen based on the DS o the
presumed source case should be started.
Te 2-month riampicin regimen (2HRZE/6HE) is associated with more relapses anddeaths than the 6-month riampicin regimen (2HRZE/4HR) (7). WHO thereore rec-
ommends the ollowing or new patients presumed or known to have drug-suscepti-
ble B. (See also Standard 8 o the ISC (3).)
L Recommendation 1.1
New patients with pulmonary B should receive a regimen containing 6 months
o riampicin: 2HRZE/4HR
(Strong/High grade o evidence)
Remark a: Recommendation 1.1 also applies to extrapulmonary B except B o
the central nervous system, bone or joint or which some expert groups suggest
longer therapy (see Chapter 8).
Remark b: WHO recommends that national B control programmes provide su-
pervision and support or all B patients in order to ensure completion o the ull
course o therapy.
Remark c: WHO recommends drug resistance surveys (or surveillance) or moni-
toring the impact o the treatment programme, as well as or designing standardregimens.
7/31/2019 A 110525 Meden Ttotg
44/150
33
L Recommendation 1.2
Te 2HRZE/6HE treatment regimen should be phased out
(Strong/High grade o evidence)
In terms o dosing requency or HIV-negative patients, the systematic review ound
little evidence o dierences in ailure or relapse rates with daily or three times week-
ly regimens (7). However, patients receiving three times weekly dosing throughout
therapy had higher rates o acquired drug resistance than patients who received
drugs daily throughout treatment. In patients with pre-treatment isoniazid resist-
ance, three times weekly dosing during the intensive phase was associated with
signicantly higher risks o ailure and acquired drug resistance than daily dosing
during the intensive phase. (reatment regimens or B patients living with HIV are
discussed in detail in Chapter 5.)
L Recommendation 2.1
Wherever easible, the optimal dosing requency or new patients with pulmo-
nary B is daily throughout the course o therapy
(Strong/High grade o evidence)
Tere are two alternatives to Recommendation 2.1:
L Recommendation 2.1A
New patients with pulmonary B may receive a daily intensive phase ol-lowed by three times weekly continuation phase [2HRZE/4(HR)
3] provided
that each dose is directly observed
(Conditional/High or moderate grade o evidence))
L Recommendation 2.1B
Tree times weekly dosing throughout therapy [2(HRZE)3/4(HR)
3] is anoth-
er alternative to Recommendation 2.1, provided that every dose is directly
observed and the patient is NO living with HIV or living in an HIV-prev-
alent setting
(Conditional/High or moderate grade o evidence))
Remark a: reatment regimens or B patients living with HIV or living in
HIV-prevalent settings are discussed in Recommendation 4 and Chapter 5.
Remark b: In terms o dosing requency or HIV-negative patients, the sys-
tematic review ound little evidence o dierences in ailure or relapse rates
with daily or three times weekly regimens (7). However, rates o acquired drug
resistance were higher among patients receiving three times weekly dosingthroughout therapy than among patients who received daily drug administra-
tion throughout treatment. Moreover, in patients with pretreatment isoniazid
resistance, three times weekly dosing during the intensive phase was associ-
3. STandard TrEaTmEnT rEGImEnS
7/31/2019 A 110525 Meden Ttotg
45/150
34
TrEaTmEnT o TubErCuloSIS: GuIdElInES
ated with signicantly higher risks o ailure and acquired drug resistance than
daily dosing during the intensive phase.
Tere is insucient evidence to support the ecacy o twice weekly dosing through-
out therapy (7).
L Recommendation 2.2
New patients with B should not receive twice weekly dosing or the ull course
o treatment unless this is done in the context o ormal research
(Strong/High grade o evidence)
Remark: Te available evidence showed equivalent ecacy o daily intensive-
phase dosing ollowed by two times weekly continuation phase (7). However, twice
weekly dosing is not recommended on operational grounds, since missing onedose means the patient receives only hal the regimen.
ables 3.2a and 3.2b present standard treatment regimen and dosing requency or
new B patients.
Tab 3.2a STAndArd regimenS or new TB pATienTS
(s, k, t hav -sstb TB)
Itesive phse tetet Ctiti phse
2 ths HrZea 4 ths Hr
a wHo s ss thabt th tsv has tatt
atts th -avta, sa-atv pTB epTB h a k t b HiV-atv. i tb-
s ts, thabt sh b a b stt.
H = saz, r = a, Z = aza, e = thabt, S = stt
Tab 3.2b doSing requency or new TB pATienTS
Recommended